Press-release for stocks related to cancer for cstl

| 27.26% | O: -0.26% H: 1.37% C: -3.32%
decisiondx melanoma cancer sentinel

Castle Biosciences, Leading Skin Cancer Expert, Darrell Rigel, M.D., M.S., and IMPACT Melanoma Board Member to Ring Nasdaq Closing Bell on Sept. 27, 2023, to Raise Awareness of Melanoma
Published: 2023-09-25 (Crawled : 12:00) - biospace.com/
CSTL | $19.61 1.55% 1.63% 95K

| 18.7% | O: 0.85% H: 0.0% C: -0.84%
melanoma nasdaq bell cancer impact skin

Castle Biosciences to Present New DecisionDx®-SCC and DecisionDx®-Melanoma Data at the American Head & Neck Society’s (AHNS) 11th International Conference on Head and Neck Cancer
Published: 2023-07-07 (Crawled : 15:00) - biospace.com/
CSTL | $19.61 1.55% 1.63% 95K

| 47.67% | O: 50.6% H: 4.8% C: 1.5%
decisiondx conference cancer international

Study Data from Castle Biosciences’ Collaboration with the National Cancer Institute’s SEER Program Registries Published in JCO Precision Oncology
Published: 2023-06-30 (Crawled : 16:00) - biospace.com/
CSTL | $19.61 1.55% 1.63% 95K

| 47.89% | O: 0.83% H: 3.96% C: 2.62%
cancer collaboration program study

Castle Biosciences Celebrates Skin Cancer Awareness Month
Published: 2023-05-30 (Crawled : 12:20) - biospace.com/
CSTL | $19.61 1.55% 1.63% 95K

| -24.58% | O: 0.04% H: 2.65% C: -5.34%
cancer skin

DecisionDx®-Melanoma Provides Improved Risk Stratification Over American Joint Committee on Cancer (AJCC) Staging Alone in Stage I Melanoma Patients
Published: 2023-04-25 (Crawled : 12:00) - biospace.com/
CSTL | $19.61 1.55% 1.63% 95K

| -17.47% | O: -1.6% H: 0.0% C: -3.34%
decisiondx melanoma cancer risk

Castle Biosciences to Highlight Clinical Value of Its Skin Cancer Tests at the 2023 American Academy of Dermatology (AAD) Annual Meeting
Published: 2023-03-10 (Crawled : 14:00) - biospace.com/
CSTL | $19.61 1.55% 1.63% 95K

| -7.85% | O: -0.14% H: 3.72% C: -8.38%
meeting skin cancer

World Molecular Diagnostics for Cancer Markets Report 2023: The New Automation, Decentralization and Point Of Care
Published: 2023-02-10 (Crawled : 01:00) - prnewswire.com
TMO | News | $548.38 0.66% 0.29% 1.5M

| -3.61% | O: -0.32% H: 0.81% C: 0.76%
NVTA | News | $0.019 0.0% 22M

| -99.14% | O: -1.8% H: 1.83% C: -4.59%
BDX | $233.88 -0.1% 0.0% 770K

| -4.63% | O: 0.18% H: 0.94% C: 0.88%
ABT | News | $107.07 -0.2% -0.09% 3.8M

| -0.93% | O: 0.18% H: 0.59% C: -0.09%
MLAB | $102.26 1.51% 2.07% 36K

| -42.64% | O: -0.73% H: 2.8% C: 2.25%
ICLR | News | $297.93 3.37% 3.33% 780K

| 27.18% | O: -0.66% H: 1.6% C: -0.18%
CSTL | $19.61 1.55% 1.63% 95K

| -25.38% | O: -0.8% H: 1.84% C: 1.53%
BIOC | $0.4349 -10.32% 750K

| -11.24% | O: 0.0% H: 1.63% C: 1.59%
TXG | $27.785 -0.56% -0.56% 1.7M

| -37.03% | O: -2.24% H: 1.83% C: 0.59%
care report diagnostics molecular cancer

Global Genomic Cancer Panel and Profiling Markets, 2023-2027: An Exploding Market as Physicians Use All the Information they Can Get in the Battle Against Cancer
Published: 2023-02-10 (Crawled : 01:00) - prnewswire.com
TMO | News | $548.38 0.66% 0.29% 1.5M

| -3.61% | O: -0.32% H: 0.81% C: 0.76%
NVTA | News | $0.019 0.0% 22M

| -99.14% | O: -1.8% H: 1.83% C: -4.59%
BDX | $233.88 -0.1% 0.0% 770K

| -4.63% | O: 0.18% H: 0.94% C: 0.88%
ABT | News | $107.07 -0.2% -0.09% 3.8M

| -0.93% | O: 0.18% H: 0.59% C: -0.09%
MLAB | $102.26 1.51% 2.07% 36K

| -42.64% | O: -0.73% H: 2.8% C: 2.25%
ICLR | News | $297.93 3.37% 3.33% 780K

| 27.18% | O: -0.66% H: 1.6% C: -0.18%
CSTL | $19.61 1.55% 1.63% 95K

| -25.38% | O: -0.8% H: 1.84% C: 1.53%
BIOC | $0.4349 -10.32% 750K

| -11.24% | O: 0.0% H: 1.63% C: 1.59%
TXG | $27.785 -0.56% -0.56% 1.7M

| -37.03% | O: -2.24% H: 1.83% C: 0.59%
global genomic cancer market

Market Forecasts for Immuno-Oncology Diagnostics 2023: Sector Represents a Revolution in Cancer Therapy
Published: 2023-01-20 (Crawled : 22:00) - prnewswire.com
ABT | News | $107.07 -0.2% -0.09% 3.8M

| Email alert Add to watchlist
ANPCY | News | $1.98 338.38% 930

| Email alert Add to watchlist
BIO | $280.13 0.14% 0.0% 220K

| Email alert Add to watchlist
TXG | $27.785 -0.56% -0.56% 1.7M

| Email alert Add to watchlist
NVTA | News | $0.019 0.0% 22M

| Email alert Add to watchlist
TMO | News | $548.38 0.66% 0.29% 1.5M

| Email alert Add to watchlist
BDX | $233.88 -0.1% 0.0% 770K

| Email alert Add to watchlist
ANPCF | News | $0.148 641.22% 5K

| Email alert Add to watchlist
CSTL | $19.61 1.55% 1.63% 95K

| Email alert Add to watchlist
ICLR | News | $297.93 3.37% 3.33% 780K

| Email alert Add to watchlist
BIOC | $0.4349 -10.32% 750K

| Email alert Add to watchlist
NH | $1.35 -46.64% -1.48% 0

Technology Services

| Email alert Add to watchlist
MLAB | $102.26 1.51% 2.07% 36K

| Email alert Add to watchlist
diagnostics therapy cancer market

Global Immuno-Oncology Diagnostics Market Report 2023-2028: Diagnostic Companies and Instrumentation Suppliers are Jockeying for Position in a New Approach to Conquering Cancer
Published: 2023-01-19 (Crawled : 16:00) - prnewswire.com
ANPCY | News | $1.98 338.38% 930

| -45.89% | O: 5.84% H: 0.0% C: 0.0%
TMO | News | $548.38 0.66% 0.29% 1.5M

| -5.46% | O: -0.87% H: 2.11% C: 1.54%
NVTA | News | $0.019 0.0% 22M

| -99.26% | O: -1.74% H: 2.17% C: -4.54%
BIO | $280.13 0.14% 0.0% 220K

| -38.07% | O: -1.15% H: 1.03% C: 0.76%
BDX | $233.88 -0.1% 0.0% 770K

| -7.77% | O: -0.36% H: 1.01% C: 0.52%
CSTL | $19.61 1.55% 1.63% 95K

| -27.56% | O: -1.07% H: 1.1% C: -2.2%
BIOC | $0.4349 -10.32% 750K

| -28.67% | O: -3.0% H: 3.15% C: -1.93%
TXG | $27.785 -0.56% -0.56% 1.7M

| -39.1% | O: -2.52% H: 1.84% C: 1.08%
global companies report diagnostic diagnostics cancer market

Real-World Clinical Utility Study Published in Cancer Investigation Demonstrates the Impact of DecisionDx®-SCC Test Results in Guiding Risk-Aligned Care for Patients with Cutaneous Squamous Cell Carcinoma
Published: 2022-10-31 (Crawled : 17:00) - biospace.com/
CSTL | $19.61 1.55% 1.63% 95K

| -16.3% | O: -0.85% H: 13.95% C: 9.86%
decisiondx care test impact cancer study cell carcinoma

Castle Biosciences Presents New Data from Collaboration with the National Cancer Institute’s (NCI) Surveillance, Epidemiology and End Results (SEER) Program
Published: 2022-10-27 (Crawled : 12:00) - biospace.com/
CSTL | $19.61 1.55% 1.63% 95K

| -11.79% | O: 0.27% H: 0.43% C: -1.35%
collaboration program results cancer

Castle Biosciences to Present Data Supporting the Clinical Value of Its Suite of Skin Cancer Tests through Multiple Oral Presentations at the 2022 American Society for Dermatologic Surgery (ASDS) Annual Meeting
Published: 2022-10-10 (Crawled : 12:00) - biospace.com/
CSTL | $19.61 1.55% 1.63% 95K

| -26.33% | O: -1.09% H: 1.6% C: -8.51%
meeting skin cancer lsd

Global Genomic Cancer Panel and Profiling Markets, 2022-2026: Screening Potential Market Size, Customized Forecasting/Analysis, and Executive and Consultant Guides
Published: 2022-07-22 (Crawled : 20:00) - prnewswire.com
ANPCY | News | $1.98 338.38% 930

| Email alert Add to watchlist
TXG | $27.785 -0.56% -0.56% 1.7M

| Email alert Add to watchlist
TMO | News | $548.38 0.66% 0.29% 1.5M

| Email alert Add to watchlist
NH | $1.35 -46.64% -1.48% 0

Technology Services

| Email alert Add to watchlist
CSTL | $19.61 1.55% 1.63% 95K

| Email alert Add to watchlist
ANPCF | News | $0.148 641.22% 5K

| Email alert Add to watchlist
BDX | $233.88 -0.1% 0.0% 770K

| Email alert Add to watchlist
NVTA | News | $0.019 0.0% 22M

| Email alert Add to watchlist
global genomic potential cancer market

Castle Adds to Evidence Supporting Its Skin Cancer Test Portfolio through Multiple Data Presentations at the SDPA Annual Summer Dermatology Conference 2022
Published: 2022-06-22 (Crawled : 12:00) - biospace.com/
CSTL | $19.61 1.55% 1.63% 95K

| 15.76% | O: -4.31% H: 11.41% C: 10.61%
conference test skin cancer

Grant From Research to Prevent Blindness and Castle Biosciences Supports Medical Student Research in Ocular Cancer
Published: 2022-05-20 (Crawled : 12:20) - biospace.com/
CSTL | $19.61 1.55% 1.63% 95K

| 2.46% | O: 5.02% H: 8.26% C: 7.71%
research grant ocular cancer

Castle Biosciences Collaborates with The Sun Bus to Provide Free Skin Cancer Screenings
Published: 2022-05-10 (Crawled : 12:00) - biospace.com/
CSTL | $19.61 1.55% 1.63% 95K

| -4.11% | O: -5.33% H: 7.7% C: 4.75%
skin cancer collaboration

Castle Biosciences Announces Expanded U.S. Federal Supply Schedule Contract Covering Its Entire Dermatologic Cancer Portfolio of Tests
Published: 2022-04-29 (Crawled : 12:00) - biospace.com/
CSTL | $19.61 1.55% 1.63% 95K

| -12.49% | O: 1.34% H: 3.61% C: -1.63%
contract cancer test

Data from Independent, Pooled Analysis Show Significantly Improved Risk Predictions Over Clinical Variables for TissueCypher® Barrett’s Esophagus Test and Ability to Identify Patients at High Risk of Progressing to Esophageal Cancer
Published: 2022-04-27 (Crawled : 12:00) - biospace.com/
CSTL | $19.61 1.55% 1.63% 95K

| -16.39% | O: -3.01% H: 3.96% C: 0.66%
tissuecypher risk test cancer

← Previous
1
2
Next →

Gainers vs Losers

74%

26%

Top 10 Gainers

MTTR | News M | $4.8 175.86% 63.6% 71M

AGBA | $2.5 100.0% 56.6% 200M

Finance

MLEC | $2.47 76.43% 42.62% 78M

n/a

NUWE | $0.334 29.96% 40.99% 2.5M